Cubist Pharmaceuticals could provide potential for acquirer down the road
Optimer Pharmaceuticals (OPTR) The FDA recently approved their clostridium difficile associated diarrhea (CDAD) drug received FDA drug approval. This company is interesting because of the growing occurrences of this disease in adults and individuals in long-term care facilities. This could imply a secular growth opportunity. The stock rallied following the positive FDA news but has since slumped. For bullish investors, this may be a longer term buying opportunity.
Their partnership with Cubist Pharmaceuticals could provide potential for acquirer down the road.